Literature DB >> 16928488

Long-term survival of patients after coronary artery bypass graft surgery: comparison of the pre-stent and post-stent eras.

Guangqiang Gao1, YingXing Wu, Gary L Grunkemeier, Anthony P Furnary, Albert Starr.   

Abstract

BACKGROUND: Although coronary artery bypass graft surgery (CABG) has long been the "gold standard" for treatment of multivessel coronary artery disease, current percutaneous interventional technologies are challenging that claim. We sought to determine long-term survival after isolated CABG to establish a baseline for comparison with interventional patients.
METHODS: From 1968 through 2003, 20,835 patients underwent 22,378 isolated CABG procedures by a single surgical team. The intermittent fibrillation technique without use of cardioplegia was consistently utilized as a method of myocardial protection, using cardiopulmonary bypass. Patients were prospectively followed with direct contact at annual intervals. Age stratified survival was analyzed. Long-term survival was compared between pre-stent era patients and post-stent era patients.
RESULTS: Operative mortality was 2.5% (95% confidence interval: 2.2% to 2.7%) and remained approximately constant since 1974 despite increasing patient age and comorbidities. Follow-up was 84% complete with 172,773 patient-years. Overall 5-, 15-, 25-, and 35-year survival was 86% +/- 0.3%, 48% +/- 0.5%, 19% +/- 0.6%, and 7% +/- 1.2%. By Cox regression, older age, prior myocardial infarction, hypertension, diabetes mellitus, and history of CABG were risk factors for long-term survival. Surgery performed during the post-stent era was a protective factor for long-term survival.
CONCLUSIONS: This study presents the long-term survival of a large series of patients after CABG performed by a single surgical team with intermittent fibrillation technique. There was no difference in observed survival up to 8 years between the pre-stent and post-stent eras. This study establishes a baseline of long-term CABG survival that could be used for comparison with other methods of surgical, or nonsurgical coronary revascularization.

Entities:  

Mesh:

Year:  2006        PMID: 16928488     DOI: 10.1016/j.athoracsur.2006.04.032

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Long-Term Survival Prediction for Coronary Artery Bypass Grafting: Validation of the ASCERT Model Compared With The Society of Thoracic Surgeons Predicted Risk of Mortality.

Authors:  Timothy S Lancaster; Matthew R Schill; Jason W Greenberg; Chawannuch Ruaengsri; Richard B Schuessler; Jennifer S Lawton; Hersh S Maniar; Michael K Pasque; Marc R Moon; Ralph J Damiano; Spencer J Melby
Journal:  Ann Thorac Surg       Date:  2017-12-19       Impact factor: 4.330

2.  Surgical management of coexisting coronary artery and valvular heart disease.

Authors:  Sak Lee; Byung-Chul Chang; Kyung-Jong Yoo
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

3.  The role of combined carotid endarterectomy and coronary artery bypass grafting in the era of carotid stenting in view of long-term results.

Authors:  Eli Levy; Dimtry Yakubovitch; Ehud Rudis; Haim Anner; Giora Landsberg; Yaakov Berlatzky; Amir Elami
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-11

4.  Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.

Authors:  Benjamin Cadier; Isabelle Durand-Zaleski; Daniel Thomas; Karine Chevreul
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

5.  Modifiable risk factors remain significant causes of medium term mortality after first time Coronary artery bypass grafting.

Authors:  Babu Kunadian; Joel Dunning; Russell W J Millner
Journal:  J Cardiothorac Surg       Date:  2007-12-03       Impact factor: 1.637

6.  Changes in risk factors and exercise capacity after cardiac rehabilitation and its effect on hospital readmission.

Authors:  Farid Najafi; Mehdi Nalini; Mohammad Reza Nikbakht
Journal:  Iran Red Crescent Med J       Date:  2014-05-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.